UroGen Pharma announces FDA acceptance of new drug application for UGN-102 [Seeking Alpha]
UroGen Pharma Ltd. - Ordinary Shares (URGN)
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.urogen.com
Company Research
Source: Seeking Alpha
UGN-102 could become the first FDA-approved medicine for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer. The FDA has assigned a Prescription Drug User Fee Act goal date of June 13, 2025. "We believe that, if approved, UGN-102's ability to achieve durable complete responses and potentially reduce recurrence rates while extending treatment-free intervals will represent a significant advance in managing LG-IR-NMIBC." said Dr. Mark Schoenberg, CMO. URGN after hours to $12.76. More on UroGen Pharma UroGen Pharma's JELMYTO And UGN-102: A Strong Buy In The Urological Cancer Sector UroGen Pharma: There Is Some Potential Here UroGen Pharma Ltd. (URGN) Q2 2024 Earnings Call Transcript UroGen started at buy by EF Hutton, RTGel technology cited UroGen Pharma misses top-line and bottom-line estimates; lowers FY24 outlook Recommended For You Comments More Trending News Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
URGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
URGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
URGN alerts
High impacting UroGen Pharma Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
URGN
News
- UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024Business Wire
- ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBCBusiness Wire
- Investors in UroGen Pharma (NASDAQ:URGN) have unfortunately lost 42% over the last five years [Yahoo! Finance]Yahoo! Finance
- UroGen Pharma Ltd. (NASDAQ: URGN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $40.00 price target on the stock.MarketBeat
- UroGen Announces FDA Acceptance of its New Drug Application for UGN-102Business Wire
URGN
Earnings
- 8/13/24 - Miss
URGN
Sec Filings
- 10/24/24 - Form SC
- 10/9/24 - Form 4
- 10/9/24 - Form 3
- URGN's page on the SEC website